A PharmAsia News update on Turkish biomedical regulatory policies, including reports that the government offered industry to keep discount rates secret and an 11.7% jump in exports in the first four months of 2014.
ISTANBUL – Turkey’s government has told industry to keep discount prices “secret” and thereby solve the problem of international benchmarking. Exports jump in the first four months, Recordati Ilac announces new investment in Turkey and a new crackdown on fake drugs is launched.
Finally, the Social Security Institution of Turkey, or SGK, added three generic drugs on the reimbursement list. For the previous...
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
EFPIA says reforms make the continent less attractive for innovative firms.
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
